What is HC Wainwright’s Forecast for Valneva Q4 Earnings?

Valneva SE (NASDAQ:VALN) – Investment analysts at HC Wainwright decreased their Q4 2024 EPS estimates for Valneva in a report issued on Wednesday, February 19th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($0.17) per share for the quarter, down from their previous forecast of ($0.15). HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Valneva’s Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.36) EPS, FY2026 earnings at ($1.23) EPS and FY2027 earnings at ($1.28) EPS.

Valneva Price Performance

VALN opened at $7.44 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The company has a market cap of $604.57 million, a price-to-earnings ratio of -57.23 and a beta of 1.98. The stock has a fifty day simple moving average of $5.25 and a two-hundred day simple moving average of $5.68. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VALN. ABC Arbitrage SA bought a new position in shares of Valneva during the fourth quarter valued at $84,000. AlphaCentric Advisors LLC increased its stake in Valneva by 33.7% during the 3rd quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock valued at $717,000 after purchasing an additional 29,748 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock worth $1,079,000 after buying an additional 30,859 shares during the last quarter. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.